| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antipsychotic Agents | 17 | 2025 | 375 | 2.720 |
Why?
|
| Coronary Vessel Anomalies | 14 | 2023 | 274 | 2.000 |
Why?
|
| Schizophrenia | 10 | 2025 | 299 | 1.890 |
Why?
|
| Liver Diseases | 8 | 2023 | 363 | 1.850 |
Why?
|
| Antidepressive Agents | 8 | 2020 | 288 | 1.730 |
Why?
|
| Computed Tomography Angiography | 14 | 2024 | 197 | 1.720 |
Why?
|
| Depressive Disorder, Major | 9 | 2025 | 399 | 1.720 |
Why?
|
| Piperazines | 9 | 2025 | 230 | 1.680 |
Why?
|
| Bipolar Disorder | 10 | 2019 | 347 | 1.660 |
Why?
|
| Cystic Fibrosis | 6 | 2023 | 257 | 1.390 |
Why?
|
| Hepatoblastoma | 9 | 2023 | 179 | 1.260 |
Why?
|
| Liver Neoplasms | 13 | 2023 | 1311 | 1.210 |
Why?
|
| Elasticity Imaging Techniques | 5 | 2023 | 124 | 1.120 |
Why?
|
| Insurance Claim Review | 1 | 2025 | 27 | 0.970 |
Why?
|
| Liver | 10 | 2023 | 1734 | 0.930 |
Why?
|
| Renal Artery Obstruction | 2 | 2021 | 41 | 0.920 |
Why?
|
| Paroxetine | 7 | 2009 | 29 | 0.910 |
Why?
|
| Quinolones | 3 | 2017 | 54 | 0.870 |
Why?
|
| Rhabdomyoma | 1 | 2022 | 16 | 0.810 |
Why?
|
| Heart Neoplasms | 1 | 2022 | 100 | 0.760 |
Why?
|
| Magnetic Resonance Imaging | 14 | 2023 | 3545 | 0.750 |
Why?
|
| Tuberous Sclerosis | 1 | 2022 | 121 | 0.740 |
Why?
|
| Humans | 112 | 2025 | 123103 | 0.680 |
Why?
|
| Thiazoles | 4 | 2015 | 97 | 0.670 |
Why?
|
| Mental Disorders | 4 | 2025 | 826 | 0.660 |
Why?
|
| Mental Health | 1 | 2021 | 347 | 0.600 |
Why?
|
| Coronary Artery Disease | 5 | 2023 | 748 | 0.600 |
Why?
|
| Coronary Angiography | 10 | 2024 | 420 | 0.600 |
Why?
|
| Child | 47 | 2024 | 24228 | 0.600 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2020 | 713 | 0.600 |
Why?
|
| Death, Sudden, Cardiac | 6 | 2024 | 248 | 0.560 |
Why?
|
| Psychomotor Agitation | 1 | 2017 | 56 | 0.560 |
Why?
|
| Myocardial Perfusion Imaging | 7 | 2024 | 57 | 0.540 |
Why?
|
| Psychotropic Drugs | 2 | 2017 | 124 | 0.540 |
Why?
|
| Jejunal Diseases | 1 | 2016 | 15 | 0.540 |
Why?
|
| Irritable Bowel Syndrome | 3 | 2009 | 205 | 0.530 |
Why?
|
| Coronary Vessels | 6 | 2023 | 526 | 0.520 |
Why?
|
| Fistula | 1 | 2016 | 50 | 0.520 |
Why?
|
| Colonic Diseases | 1 | 2016 | 38 | 0.520 |
Why?
|
| Drug Discovery | 1 | 2017 | 170 | 0.510 |
Why?
|
| Psychotic Disorders | 3 | 2007 | 140 | 0.500 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2016 | 88 | 0.500 |
Why?
|
| Dibenzothiazepines | 1 | 2015 | 14 | 0.490 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 352 | 0.480 |
Why?
|
| Myocardial Ischemia | 3 | 2023 | 332 | 0.470 |
Why?
|
| Male | 57 | 2025 | 60129 | 0.450 |
Why?
|
| Aorta, Thoracic | 4 | 2021 | 520 | 0.440 |
Why?
|
| Sarcoma | 1 | 2016 | 194 | 0.440 |
Why?
|
| Vascular Malformations | 4 | 2021 | 81 | 0.430 |
Why?
|
| Female | 54 | 2025 | 65514 | 0.410 |
Why?
|
| Retrospective Studies | 25 | 2025 | 16044 | 0.390 |
Why?
|
| Treatment Outcome | 26 | 2024 | 12115 | 0.390 |
Why?
|
| Aorta | 8 | 2023 | 542 | 0.390 |
Why?
|
| Magnetic Resonance Imaging, Cine | 4 | 2023 | 149 | 0.390 |
Why?
|
| Psychiatric Status Rating Scales | 10 | 2015 | 805 | 0.380 |
Why?
|
| Adolescent | 26 | 2025 | 19094 | 0.370 |
Why?
|
| Adult | 29 | 2025 | 29009 | 0.360 |
Why?
|
| Contrast Media | 6 | 2020 | 470 | 0.350 |
Why?
|
| Drug Therapy, Combination | 5 | 2017 | 1138 | 0.350 |
Why?
|
| Argininosuccinate Lyase | 2 | 2021 | 59 | 0.340 |
Why?
|
| Patient Compliance | 4 | 2007 | 464 | 0.340 |
Why?
|
| Aripiprazole | 3 | 2017 | 21 | 0.340 |
Why?
|
| Anxiety Disorders | 3 | 2009 | 677 | 0.330 |
Why?
|
| Double-Blind Method | 13 | 2019 | 1583 | 0.330 |
Why?
|
| Patient Care Team | 3 | 2020 | 548 | 0.330 |
Why?
|
| Ductus Arteriosus, Patent | 2 | 2022 | 145 | 0.330 |
Why?
|
| Monoamine Oxidase Inhibitors | 2 | 2006 | 12 | 0.320 |
Why?
|
| Prospective Studies | 14 | 2024 | 6028 | 0.320 |
Why?
|
| Heart Ventricles | 3 | 2023 | 762 | 0.300 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2021 | 938 | 0.300 |
Why?
|
| Delayed-Action Preparations | 10 | 2017 | 110 | 0.290 |
Why?
|
| Child, Preschool | 19 | 2022 | 13888 | 0.280 |
Why?
|
| Antidepressive Agents, Second-Generation | 2 | 2009 | 36 | 0.280 |
Why?
|
| Diagnostic Imaging | 2 | 2022 | 270 | 0.280 |
Why?
|
| Infant | 17 | 2023 | 12357 | 0.270 |
Why?
|
| Selegiline | 1 | 2006 | 7 | 0.270 |
Why?
|
| Ketamine | 2 | 2020 | 214 | 0.260 |
Why?
|
| Cyclohexanols | 2 | 2003 | 6 | 0.260 |
Why?
|
| Endocrine System Diseases | 1 | 2005 | 37 | 0.250 |
Why?
|
| Embolization, Therapeutic | 3 | 2021 | 227 | 0.250 |
Why?
|
| Sick Leave | 1 | 2025 | 5 | 0.250 |
Why?
|
| Metabolic Syndrome | 2 | 2007 | 329 | 0.250 |
Why?
|
| Young Adult | 9 | 2025 | 8855 | 0.240 |
Why?
|
| Postoperative Complications | 5 | 2021 | 3011 | 0.240 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2023 | 2055 | 0.240 |
Why?
|
| Liver Transplantation | 4 | 2018 | 1015 | 0.230 |
Why?
|
| Heart Defects, Congenital | 4 | 2022 | 1804 | 0.230 |
Why?
|
| Glypicans | 1 | 2024 | 39 | 0.230 |
Why?
|
| Depressive Disorder | 2 | 2009 | 451 | 0.230 |
Why?
|
| Practice Guidelines as Topic | 6 | 2020 | 1258 | 0.230 |
Why?
|
| Exercise | 2 | 2021 | 813 | 0.230 |
Why?
|
| Fibromyalgia | 3 | 2009 | 17 | 0.230 |
Why?
|
| Cardiac Catheterization | 4 | 2024 | 631 | 0.230 |
Why?
|
| Interleukin-15 | 1 | 2024 | 91 | 0.230 |
Why?
|
| Metabolic Diseases | 1 | 2005 | 130 | 0.230 |
Why?
|
| Insurance, Health | 1 | 2025 | 138 | 0.230 |
Why?
|
| Myocardial Bridging | 1 | 2024 | 12 | 0.220 |
Why?
|
| Health Expenditures | 1 | 2025 | 103 | 0.220 |
Why?
|
| Aged | 8 | 2024 | 19093 | 0.220 |
Why?
|
| Schizophrenic Psychology | 2 | 2017 | 81 | 0.220 |
Why?
|
| Clinical Trials as Topic | 5 | 2017 | 1080 | 0.220 |
Why?
|
| Fractional Flow Reserve, Myocardial | 2 | 2021 | 41 | 0.210 |
Why?
|
| Urea Cycle Disorders, Inborn | 2 | 2021 | 77 | 0.210 |
Why?
|
| Middle Aged | 18 | 2025 | 25992 | 0.210 |
Why?
|
| Stenosis, Pulmonary Vein | 1 | 2023 | 19 | 0.210 |
Why?
|
| Pandemics | 2 | 2021 | 1101 | 0.210 |
Why?
|
| Liver Cirrhosis | 4 | 2023 | 823 | 0.210 |
Why?
|
| Informed Consent | 3 | 2008 | 341 | 0.210 |
Why?
|
| Replantation | 2 | 2021 | 54 | 0.210 |
Why?
|
| Akathisia, Drug-Induced | 1 | 2002 | 11 | 0.210 |
Why?
|
| Isolated Noncompaction of the Ventricular Myocardium | 1 | 2023 | 43 | 0.210 |
Why?
|
| Colonic Diseases, Functional | 1 | 2002 | 14 | 0.210 |
Why?
|
| Mianserin | 1 | 2002 | 3 | 0.210 |
Why?
|
| Predictive Value of Tests | 7 | 2023 | 2112 | 0.210 |
Why?
|
| Surface Plasmon Resonance | 1 | 2022 | 45 | 0.210 |
Why?
|
| Bupropion | 1 | 2002 | 27 | 0.200 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2018 | 389 | 0.200 |
Why?
|
| Mood Disorders | 2 | 2020 | 125 | 0.200 |
Why?
|
| Ductus Arteriosus | 1 | 2022 | 63 | 0.200 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2004 | 254 | 0.200 |
Why?
|
| Angiography | 4 | 2023 | 215 | 0.200 |
Why?
|
| Adenosine A2 Receptor Agonists | 2 | 2019 | 15 | 0.190 |
Why?
|
| Aneurysm, False | 1 | 2023 | 102 | 0.190 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2022 | 64 | 0.190 |
Why?
|
| Yttrium Radioisotopes | 1 | 2021 | 18 | 0.190 |
Why?
|
| Triazoles | 1 | 2002 | 138 | 0.190 |
Why?
|
| Hypertension, Portal | 1 | 2022 | 78 | 0.190 |
Why?
|
| Purines | 2 | 2019 | 107 | 0.190 |
Why?
|
| Renal Artery | 1 | 2021 | 74 | 0.190 |
Why?
|
| Prognosis | 5 | 2023 | 4512 | 0.180 |
Why?
|
| Severity of Illness Index | 5 | 2020 | 2847 | 0.180 |
Why?
|
| Diagnosis, Differential | 5 | 2019 | 1876 | 0.180 |
Why?
|
| Dimensional Measurement Accuracy | 1 | 2020 | 4 | 0.180 |
Why?
|
| Radiology Department, Hospital | 1 | 2020 | 24 | 0.170 |
Why?
|
| Liver Glycogen | 1 | 2020 | 22 | 0.170 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2020 | 20 | 0.170 |
Why?
|
| Twins, Conjoined | 1 | 2020 | 29 | 0.170 |
Why?
|
| Norwood Procedures | 1 | 2021 | 100 | 0.170 |
Why?
|
| Printing, Three-Dimensional | 1 | 2020 | 68 | 0.170 |
Why?
|
| Models, Anatomic | 1 | 2020 | 98 | 0.160 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2019 | 17 | 0.160 |
Why?
|
| Ultrasonography | 4 | 2021 | 939 | 0.160 |
Why?
|
| Neurosciences | 1 | 2019 | 50 | 0.160 |
Why?
|
| Positive-Pressure Respiration | 1 | 2019 | 83 | 0.160 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2019 | 96 | 0.160 |
Why?
|
| Pyrazoles | 2 | 2019 | 304 | 0.160 |
Why?
|
| Physician-Patient Relations | 1 | 2002 | 428 | 0.160 |
Why?
|
| Heart Arrest | 1 | 2023 | 341 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2017 | 1071 | 0.160 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2019 | 148 | 0.150 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 1 | 2020 | 115 | 0.150 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2019 | 73 | 0.150 |
Why?
|
| Cystine Depleting Agents | 1 | 2018 | 2 | 0.150 |
Why?
|
| Lymphography | 1 | 2018 | 12 | 0.150 |
Why?
|
| Cysteamine | 1 | 2018 | 14 | 0.150 |
Why?
|
| Infant, Newborn | 8 | 2020 | 8106 | 0.150 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 862 | 0.150 |
Why?
|
| Arterial Switch Operation | 1 | 2018 | 22 | 0.150 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2019 | 111 | 0.150 |
Why?
|
| Lymphatic Diseases | 1 | 2018 | 31 | 0.150 |
Why?
|
| Methylphenidate | 2 | 2009 | 55 | 0.150 |
Why?
|
| Paliperidone Palmitate | 1 | 2017 | 4 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2016 | 353 | 0.150 |
Why?
|
| Hypoplastic Left Heart Syndrome | 1 | 2021 | 252 | 0.150 |
Why?
|
| Mental Competency | 1 | 1998 | 51 | 0.150 |
Why?
|
| Umbilical Veins | 1 | 2017 | 71 | 0.140 |
Why?
|
| Coronary Sinus | 1 | 2017 | 14 | 0.140 |
Why?
|
| Hodgkin Disease | 1 | 2020 | 293 | 0.140 |
Why?
|
| Drug Evaluation | 1 | 2017 | 111 | 0.140 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2024 | 1099 | 0.140 |
Why?
|
| Hemangioma | 1 | 2018 | 95 | 0.140 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2006 | 772 | 0.140 |
Why?
|
| Fibrinolytic Agents | 1 | 2019 | 198 | 0.140 |
Why?
|
| Emergency Services, Psychiatric | 1 | 2017 | 20 | 0.140 |
Why?
|
| Serotonin Agents | 1 | 2017 | 14 | 0.140 |
Why?
|
| Follow-Up Studies | 6 | 2022 | 5039 | 0.140 |
Why?
|
| Central Nervous System Stimulants | 2 | 2009 | 125 | 0.140 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2021 | 448 | 0.140 |
Why?
|
| Hepatectomy | 3 | 2023 | 109 | 0.140 |
Why?
|
| Image Enhancement | 1 | 2018 | 166 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 286 | 0.140 |
Why?
|
| Thiophenes | 1 | 2017 | 60 | 0.130 |
Why?
|
| Chest Pain | 1 | 2017 | 124 | 0.130 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2019 | 184 | 0.130 |
Why?
|
| Aortic Diseases | 1 | 2019 | 197 | 0.130 |
Why?
|
| Depression | 2 | 2019 | 1227 | 0.130 |
Why?
|
| Electroconvulsive Therapy | 1 | 2017 | 66 | 0.130 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2018 | 224 | 0.130 |
Why?
|
| Gastroscopy | 1 | 2016 | 102 | 0.130 |
Why?
|
| T-Lymphocytes | 1 | 2024 | 1690 | 0.130 |
Why?
|
| Exercise Test | 3 | 2024 | 249 | 0.130 |
Why?
|
| Child Abuse | 2 | 2009 | 195 | 0.130 |
Why?
|
| Drug Interactions | 3 | 2008 | 253 | 0.130 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2016 | 80 | 0.130 |
Why?
|
| Metastasectomy | 1 | 2015 | 10 | 0.130 |
Why?
|
| Surveys and Questionnaires | 7 | 2022 | 3664 | 0.130 |
Why?
|
| Adenoma, Liver Cell | 1 | 2015 | 4 | 0.120 |
Why?
|
| Sexual Dysfunction, Physiological | 2 | 2009 | 71 | 0.120 |
Why?
|
| Quetiapine Fumarate | 1 | 2015 | 16 | 0.120 |
Why?
|
| Hernia, Abdominal | 1 | 2015 | 18 | 0.120 |
Why?
|
| Pain Measurement | 4 | 2009 | 358 | 0.120 |
Why?
|
| Drug Dosage Calculations | 1 | 2015 | 19 | 0.120 |
Why?
|
| Aggression | 1 | 2017 | 225 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 358 | 0.120 |
Why?
|
| Duodenal Diseases | 1 | 2015 | 34 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 374 | 0.120 |
Why?
|
| Brain Diseases | 1 | 2018 | 299 | 0.120 |
Why?
|
| Focal Nodular Hyperplasia | 1 | 2014 | 6 | 0.120 |
Why?
|
| Quality of Life | 2 | 2022 | 1923 | 0.120 |
Why?
|
| Intestinal Volvulus | 1 | 2015 | 36 | 0.120 |
Why?
|
| Risk Factors | 6 | 2020 | 10018 | 0.120 |
Why?
|
| United States | 4 | 2025 | 10651 | 0.120 |
Why?
|
| Respiration | 1 | 2015 | 122 | 0.120 |
Why?
|
| Health Status | 2 | 2022 | 374 | 0.120 |
Why?
|
| Pneumonectomy | 1 | 2015 | 129 | 0.120 |
Why?
|
| Vascular Surgical Procedures | 2 | 2017 | 565 | 0.120 |
Why?
|
| Surgical Procedures, Operative | 1 | 2016 | 181 | 0.110 |
Why?
|
| Isoindoles | 1 | 2013 | 3 | 0.110 |
Why?
|
| Referral and Consultation | 1 | 1998 | 529 | 0.110 |
Why?
|
| Thrombosis | 1 | 2019 | 520 | 0.110 |
Why?
|
| Disease Progression | 1 | 2020 | 2028 | 0.110 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2013 | 25 | 0.110 |
Why?
|
| Hemangiosarcoma | 1 | 2014 | 38 | 0.110 |
Why?
|
| Isoxazoles | 1 | 2013 | 31 | 0.110 |
Why?
|
| Echocardiography | 4 | 2023 | 1049 | 0.110 |
Why?
|
| Stents | 1 | 2020 | 877 | 0.110 |
Why?
|
| Venlafaxine Hydrochloride | 2 | 2003 | 10 | 0.110 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2014 | 126 | 0.110 |
Why?
|
| Chronic Pain | 1 | 2015 | 127 | 0.110 |
Why?
|
| Indoles | 1 | 2013 | 180 | 0.100 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 1 | 2017 | 395 | 0.100 |
Why?
|
| Abdominal Pain | 1 | 2015 | 306 | 0.100 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 1236 | 0.100 |
Why?
|
| Appendicitis | 1 | 2014 | 128 | 0.100 |
Why?
|
| Imidazoles | 1 | 2013 | 193 | 0.100 |
Why?
|
| Sirolimus | 1 | 2014 | 220 | 0.100 |
Why?
|
| Constriction, Pathologic | 2 | 2023 | 240 | 0.100 |
Why?
|
| Piperidines | 1 | 2013 | 200 | 0.100 |
Why?
|
| Recurrence | 2 | 2023 | 1419 | 0.100 |
Why?
|
| Child Abuse, Sexual | 2 | 2009 | 34 | 0.100 |
Why?
|
| Lung | 1 | 2019 | 1463 | 0.100 |
Why?
|
| Subclavian Artery | 1 | 2012 | 71 | 0.090 |
Why?
|
| Weight Gain | 2 | 2006 | 401 | 0.090 |
Why?
|
| Comorbidity | 3 | 2007 | 1497 | 0.090 |
Why?
|
| Proxy | 1 | 2010 | 15 | 0.090 |
Why?
|
| New York | 2 | 2002 | 68 | 0.090 |
Why?
|
| Time Factors | 3 | 2020 | 6219 | 0.090 |
Why?
|
| Neoplasms | 1 | 2024 | 2755 | 0.090 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 642 | 0.090 |
Why?
|
| Analysis of Variance | 2 | 2009 | 1009 | 0.080 |
Why?
|
| Psychophysiologic Disorders | 1 | 2009 | 24 | 0.080 |
Why?
|
| Secondary Prevention | 1 | 2010 | 212 | 0.080 |
Why?
|
| ROC Curve | 1 | 2010 | 558 | 0.080 |
Why?
|
| Sensitivity and Specificity | 3 | 2020 | 2011 | 0.080 |
Why?
|
| Placebos | 1 | 2009 | 238 | 0.080 |
Why?
|
| Electronic Health Records | 1 | 2015 | 710 | 0.070 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2006 | 202 | 0.070 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2021 | 360 | 0.070 |
Why?
|
| Outpatients | 1 | 2009 | 254 | 0.070 |
Why?
|
| Polypharmacy | 1 | 2007 | 40 | 0.070 |
Why?
|
| Risk Assessment | 3 | 2020 | 3325 | 0.070 |
Why?
|
| Naltrexone | 1 | 2007 | 69 | 0.070 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 586 | 0.070 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2007 | 28 | 0.070 |
Why?
|
| Hemodynamics | 2 | 2024 | 844 | 0.070 |
Why?
|
| Cerebral Arteries | 1 | 2007 | 79 | 0.070 |
Why?
|
| Arteriovenous Fistula | 1 | 2007 | 56 | 0.070 |
Why?
|
| Tranylcypromine | 1 | 2006 | 1 | 0.070 |
Why?
|
| Phenelzine | 1 | 2006 | 4 | 0.070 |
Why?
|
| Administration, Cutaneous | 1 | 2006 | 61 | 0.070 |
Why?
|
| Lung Neoplasms | 1 | 2015 | 1593 | 0.060 |
Why?
|
| Abnormalities, Multiple | 1 | 2012 | 962 | 0.060 |
Why?
|
| Hyperprolactinemia | 1 | 2005 | 17 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2019 | 3369 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2005 | 1230 | 0.060 |
Why?
|
| Psychiatry | 1 | 2008 | 263 | 0.060 |
Why?
|
| Alcoholism | 1 | 2007 | 230 | 0.060 |
Why?
|
| Reoperation | 2 | 2021 | 818 | 0.060 |
Why?
|
| Research Design | 1 | 2008 | 676 | 0.060 |
Why?
|
| Heart | 2 | 2021 | 723 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2024 | 4699 | 0.060 |
Why?
|
| Sleep Wake Disorders | 1 | 2007 | 177 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1118 | 0.060 |
Why?
|
| Myocardium | 1 | 2009 | 986 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2009 | 1681 | 0.060 |
Why?
|
| Stress, Psychological | 1 | 2009 | 556 | 0.060 |
Why?
|
| Biopsy | 2 | 2020 | 1236 | 0.060 |
Why?
|
| Buspirone | 1 | 2003 | 12 | 0.060 |
Why?
|
| Pulmonary Artery | 2 | 2023 | 439 | 0.060 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2003 | 23 | 0.060 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2003 | 26 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2023 | 51 | 0.050 |
Why?
|
| Injections, Intramuscular | 2 | 2017 | 192 | 0.050 |
Why?
|
| Platelet Count | 1 | 2023 | 133 | 0.050 |
Why?
|
| Self Disclosure | 1 | 2002 | 24 | 0.050 |
Why?
|
| Pregnancy Complications | 1 | 2007 | 507 | 0.050 |
Why?
|
| Catheters | 1 | 2023 | 89 | 0.050 |
Why?
|
| Family | 1 | 2006 | 571 | 0.050 |
Why?
|
| Fatal Outcome | 2 | 2018 | 355 | 0.050 |
Why?
|
| Cattle | 1 | 2023 | 557 | 0.050 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2002 | 165 | 0.050 |
Why?
|
| Shock, Cardiogenic | 1 | 2023 | 187 | 0.050 |
Why?
|
| Stroke Volume | 1 | 2023 | 445 | 0.050 |
Why?
|
| Dobutamine | 1 | 2021 | 55 | 0.050 |
Why?
|
| Hyperammonemia | 1 | 2021 | 60 | 0.050 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2020 | 51 | 0.040 |
Why?
|
| Indocyanine Green | 1 | 2021 | 58 | 0.040 |
Why?
|
| Organizational Objectives | 1 | 2020 | 33 | 0.040 |
Why?
|
| Optical Imaging | 1 | 2021 | 66 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2023 | 756 | 0.040 |
Why?
|
| Cardiac-Gated Imaging Techniques | 1 | 2020 | 7 | 0.040 |
Why?
|
| Biomarkers | 2 | 2021 | 2943 | 0.040 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2022 | 223 | 0.040 |
Why?
|
| Radiology Information Systems | 1 | 2020 | 23 | 0.040 |
Why?
|
| Electrocardiography | 2 | 2020 | 957 | 0.040 |
Why?
|
| Movement Disorders | 1 | 2003 | 221 | 0.040 |
Why?
|
| Triiodobenzoic Acids | 1 | 2020 | 28 | 0.040 |
Why?
|
| Coronary Stenosis | 1 | 2021 | 71 | 0.040 |
Why?
|
| Ischemia | 1 | 2023 | 343 | 0.040 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2020 | 48 | 0.040 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2020 | 169 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 54 | 0.040 |
Why?
|
| Perfusion | 1 | 2021 | 198 | 0.040 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2021 | 113 | 0.040 |
Why?
|
| Ventricular Function, Left | 1 | 2023 | 496 | 0.040 |
Why?
|
| Workplace | 1 | 2020 | 69 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2020 | 150 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2018 | 1389 | 0.040 |
Why?
|
| Prevalence | 1 | 2006 | 2395 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2017 | 1473 | 0.040 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2023 | 533 | 0.040 |
Why?
|
| Cytokines | 1 | 2024 | 1284 | 0.040 |
Why?
|
| Emergencies | 1 | 2020 | 174 | 0.040 |
Why?
|
| Hemangioendothelioma | 1 | 2018 | 25 | 0.040 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2024 | 819 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2020 | 233 | 0.040 |
Why?
|
| Chylous Ascites | 1 | 2018 | 11 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2021 | 577 | 0.040 |
Why?
|
| Myocardial Infarction | 1 | 2005 | 1001 | 0.040 |
Why?
|
| Chylothorax | 1 | 2018 | 27 | 0.040 |
Why?
|
| Ligation | 1 | 2018 | 132 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 265 | 0.040 |
Why?
|
| Survivors | 1 | 2020 | 345 | 0.040 |
Why?
|
| Protons | 1 | 2018 | 91 | 0.040 |
Why?
|
| Ultrasonography, Doppler | 1 | 2018 | 197 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2024 | 2307 | 0.040 |
Why?
|
| Treatment Refusal | 1 | 1998 | 77 | 0.040 |
Why?
|
| Thrombolytic Therapy | 1 | 2019 | 204 | 0.040 |
Why?
|
| Consensus | 1 | 2020 | 607 | 0.030 |
Why?
|
| Palliative Care | 1 | 2021 | 428 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2018 | 214 | 0.030 |
Why?
|
| Herniorrhaphy | 1 | 2017 | 80 | 0.030 |
Why?
|
| Transposition of Great Vessels | 1 | 2018 | 131 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 280 | 0.030 |
Why?
|
| Coronary Artery Bypass | 1 | 2020 | 489 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1306 | 0.030 |
Why?
|
| Animals | 3 | 2023 | 33792 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1162 | 0.030 |
Why?
|
| Fibrosis | 1 | 2017 | 429 | 0.030 |
Why?
|
| Heart Rate | 1 | 2018 | 587 | 0.030 |
Why?
|
| Multidetector Computed Tomography | 1 | 2015 | 35 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 604 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2020 | 781 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2020 | 1172 | 0.030 |
Why?
|
| Intraoperative Care | 1 | 2015 | 103 | 0.030 |
Why?
|
| Necrosis | 1 | 2015 | 205 | 0.030 |
Why?
|
| Conscious Sedation | 1 | 2015 | 63 | 0.030 |
Why?
|
| Dibenzocycloheptenes | 1 | 2013 | 3 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2015 | 310 | 0.030 |
Why?
|
| Lurasidone Hydrochloride | 1 | 2013 | 2 | 0.030 |
Why?
|
| Obesity | 1 | 2005 | 2230 | 0.030 |
Why?
|
| Patient Discharge | 1 | 1998 | 491 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2015 | 120 | 0.030 |
Why?
|
| Drug Approval | 1 | 2013 | 40 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 2799 | 0.030 |
Why?
|
| Algorithms | 1 | 2020 | 1598 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2020 | 3234 | 0.030 |
Why?
|
| Incidence | 1 | 2020 | 3039 | 0.030 |
Why?
|
| Mass Screening | 1 | 2018 | 786 | 0.030 |
Why?
|
| Registries | 1 | 2018 | 1394 | 0.020 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2012 | 114 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2015 | 327 | 0.020 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2012 | 133 | 0.020 |
Why?
|
| Intestines | 1 | 2015 | 570 | 0.020 |
Why?
|
| Pregnancy | 3 | 2008 | 7138 | 0.020 |
Why?
|
| Korea | 1 | 2009 | 35 | 0.020 |
Why?
|
| Interview, Psychological | 1 | 2009 | 99 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 4283 | 0.020 |
Why?
|
| Pediatrics | 1 | 2018 | 1141 | 0.020 |
Why?
|
| Sick Role | 1 | 2009 | 31 | 0.020 |
Why?
|
| Acute Disease | 1 | 2012 | 1093 | 0.020 |
Why?
|
| Republic of Korea | 1 | 2008 | 37 | 0.020 |
Why?
|
| Ethics Committees, Research | 1 | 2008 | 33 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2008 | 71 | 0.020 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2008 | 64 | 0.020 |
Why?
|
| South Carolina | 1 | 2007 | 10 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2009 | 190 | 0.020 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2007 | 18 | 0.020 |
Why?
|
| Polyvinyls | 1 | 2007 | 13 | 0.020 |
Why?
|
| Narcotic Antagonists | 1 | 2007 | 104 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2007 | 159 | 0.020 |
Why?
|
| Middle Cerebral Artery | 1 | 2007 | 110 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2005 | 30 | 0.020 |
Why?
|
| Psychometrics | 1 | 2009 | 665 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2006 | 334 | 0.020 |
Why?
|
| Radiography | 1 | 2007 | 822 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 2007 | 600 | 0.010 |
Why?
|
| Poverty | 1 | 2007 | 418 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 720 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2005 | 770 | 0.010 |
Why?
|
| Mice | 1 | 2020 | 17537 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 2840 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2005 | 1242 | 0.010 |
Why?
|
| Infant, Premature | 1 | 2007 | 799 | 0.010 |
Why?
|